ArticleNature immunology2025
Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19.
Abstract read
In one paragraph
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- T-cell repertoire response in individuals with post-acute sequelae of COVID-19.bioRxiv : the preprint server for biology · 2026Article
- Distinct plasma proteome signature at 3 months post-COVID-19 infection irrespective of post-COVID condition.Scientific reports · 2026Article
- Immune Priming and the Risk of COVID-19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort.Influenza and other respiratory viruses · 2026Article
- Immune dysregulation triggered by inflammatory cytokines in patients with severe respiratory infections.Respiratory research · 2026Article
- Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins.Research square · 2026Article
- A Probabilistic Modeling Analysis of the Longitudinal Immune Response to Infection and Vaccination Across Demographic Groups and Pulmonary Symptoms.Spora : a journal of biomathematics · 2026Article
- Respiratory viral infections prime accelerated lung cancer growth.bioRxiv : the preprint server for biology · 2025Article
- HLA-B27 Status in Rheumatic Diseases: Clinical and Immunological Differences Between Positive and Negative Patients-A Comparative Study.Biomedicines · 2025Article
- Article
- Probabilistic Modeling of Antibody Kinetics Post Infection and Vaccination: A Markov Chain Approach.ArXiv · 2025Article
- Rhinovirus as a driver of airway T cell dynamics in children with treatment-refractory recurrent wheeze.JCI insight · 2025Article
- Unravelling the interplay between respiratory disease and the immune landscape in long COVID.Nature immunology · 2025Article
Corrections and comments
- Update of
Authors and funding
24 authors.
Glenda Canderan *Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-8388-9930
Lyndsey M Muehling *Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0003-3203-3264
Alexandra KadlDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Shay LaddDepartment of Biomedical Engineering, University of Virginia School of Engineering and Applied Science, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0002-6662-6255
Catherine BonhamDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-9132-4083
Claire E CrossDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-5534-9491
Sierra M LimaDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
Xihui YinDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-1861-1147
Jeffrey M SturekDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0002-2731-3299
Jeffrey M WilsonDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Behnam KeshavarzDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-5121-6950
Kyle B EnfieldDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Chintan RamaniDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Naomi BryantDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-5807-9397
Deborah D MurphyDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
In Su CheonDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Michael SolgaDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Patcharin PramoonjagoDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Coleen A McNamaraDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Jie SunDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0002-2347-4511
Paul J UtzDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1181-1565
Sepideh DolatshahiBeirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0003-0226-0933
Jonathan M IrishDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-9428-8866
Judith A WoodfolkDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. jaw4m@virginia.edu.ORCID http://orcid.org/0000-0002-8915-4334
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MWomen's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1MINTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MIgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory diseaseR37AI020565 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THOMAS A. PLATTS-MILLS · 1992 to 2026
$8.4MSingle Cell Methods for Bioeffector Discovery and AnalysisR01CA226833 · NCI · VANDERBILT UNIVERSITY · PI BRIAN O BACHMANN, Jonathan Michael Irish · 2019 to 2026
$6.1MAn Evaluation of Treatment with Omalizumab to Improve the Asthmatic Response to aU01AI100799 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYMANN, PETER W, PLATTS-MILLS, THOMAS A. · 2012 to 2015
$5.3MHost cellular network governing the development of post SARS-CoV-2 tissue sequelaeR01AI147394 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$4.7MElucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infectionR01AG069264 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$3.5MDeterminants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with AsthmaR01AI176171 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun, WILLIAM GERALD TEAGUE · 2023 to 2026
$2.7MUncover mechanisms underlying the development of chronic lung sequelae post COVID-19R01HL170961 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jie Sun, ROBERT VASSALLO · 2023 to 2026
$2.7MInterdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · NIGMS · UNIVERSITY OF VIRGINIA · PI Kevin A Janes, Jason Papin · 2022 to 2026
$1.5MCD38, T cells and post viral lung sequelae during agingR01AG090337 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2025 to 2026
$1.3MNCI NIH HHS P30 CA044579NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA226833NHLBI NIH HHS R01 HL170961NIAID NIH HHS R01 AI147394NIAID NIH HHS R01 AI176171NIAID NIH HHS R21 AI138077NIAID NIH HHS R21 AI160334NIAID NIH HHS R37 AI020565NIAID NIH HHS R56 AI178669NIAID NIH HHS T32 AI007496NIAID NIH HHS U01 AI100799NIA NIH HHS R01 AG069264NIA NIH HHS R01 AG090337NIGMS NIH HHS T32 GM145443Vanderbilt-Ingram Cancer Center (VICC) P30 CA68485
Abstract
The variable origins of persistent breathlessness after coronavirus disease 2019 (COVID-19) have hindered efforts to decipher the immunopathology of lung sequelae. Here we analyzed hundreds of cellular and molecular features in the context of discrete pulmonary phenotypes to define the systemic immune landscape of post-COVID lung disease. Cluster analysis of lung physiology measures highlighted two phenotypes of restrictive lung disease that differed according to their impaired diffusion and severity of fibrosis. Machine learning revealed marked CCR5
Indexed as
COVID-19LungSARS-CoV-2AgedAutoantibodiesCD8-Positive T-LymphocytesChemokine CXCL13FemaleHumansMaleMiddle AgedSeverity of Illness IndexAutoantibodiesChemokine CXCL13
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.